CAS 731772-50-2

Efavirenz-emtricitabine-tenofovir disoproxil fumarate mixt.

Description:

Efavirenz-emtricitabine-tenofovir disoproxil fumarate is a fixed-dose combination medication primarily used in the treatment of HIV infection. This combination includes three active ingredients: efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI); emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI); and tenofovir disoproxil fumarate, an acyclic nucleotide phosphonate that also acts as an NRTI. The combination works synergistically to inhibit viral replication by targeting different stages of the HIV life cycle. Efavirenz is known for its ability to penetrate the central nervous system, which can lead to neuropsychiatric side effects in some patients. Emtricitabine and tenofovir disoproxil fumarate are generally well-tolerated, but they can cause renal toxicity and bone density loss with long-term use. The formulation is designed for once-daily dosing, enhancing adherence to therapy. Overall, this combination therapy is a cornerstone in antiretroviral treatment regimens, contributing to improved health outcomes for individuals living with HIV.

Formula: C₁₉H₃₀N₅O₁₀P·C₁₄H₉ClF₃NO₂·C₈H₁₀FN₃O₃S·C₄H₄O₄

SMILES: C(#CC1CC1)[C@@]2(C(F)(F)F)C=3C(NC(=O)O2)=CC=C(Cl)C3.O=C1N([C@H]2O[C@@H](CO)SC2)C=C(F)C(N)=N1.C([C@H](OCP(OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)C)N1C=2C(N=C1)=C(N)N=CN2.C(=C/C(O)=O)\C(O)=O

Synonyms:

• Efavirenz-emtricitabine-tenofovir disoproxil
• Efavirenz-emtricitabine-tenofovir disoproxil fumarate mixt.
• Atripla
• 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, bis(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1), mixt. with 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone and (4S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
• Efavirenz-emtricitabine-tenofovir disoproxil fumarate

Atripla

CAS: 731772-50-2

Atripla is a medication that works as a kinase inhibitor, targeting specific kinases involved in the cell cycle of cancer cells. It is an effective treatment for various forms of cancer and has been shown to induce apoptosis, or programmed cell death, in cancer cells. Atripla is made from a combination of medicinal compounds derived from Chinese medicine and other sources. This potent inhibitor has been tested on human cell lines and has shown significant anti-tumor activity. Its unique formulation makes it an ideal choice for patients seeking alternative cancer treatments that are both safe and effective.

Formula: C₄₅H₅₃ClF₄N₉O₁₉PS

Purity: Min. 95%

Molecular weight: 1,198.4 g/mol

Ref: 3D-GEB77250